Stargazer Pharmaceuticals is a Boston-based biopharmaceutical company launched in 2018 that focuses on developing novel treatments for rare eye diseases, with an initial focus on Stargardt Disease. Its lead program is STG-001, a proprietary compound being developed specifically to treat Stargardt Disease. The company is collaborating with the Foundation Fighting Blindness (FFB), which participated in the financing via its Retinal Degeneration Fund. Stargardt Disease is a genetic orphan disease that leads to legal blindness and affects approximately 1 in 8,000 to 1 in 10,000 individuals; there are currently no approved therapies. Stargazer plans to use the recently raised capital to advance development of STG-001. The company completed a $57 million Series A to support these development efforts.

Total raised

$57M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2020